| 000 | 01663nam a22003497a 4500 | ||
|---|---|---|---|
| 999 |
_c5744 _d5744 |
||
| 001 | 00005744 | ||
| 003 | ES-MaONT | ||
| 005 | 20211006062658.0 | ||
| 008 | 200318s2020 be ||||fst|||i001 0 eng d | ||
| 020 | _a978-92-846-6037-7 | ||
| 024 |
_2doi _a10.2861/114406 |
||
| 040 | _aES-MaONT | ||
| 245 | 0 | 4 |
_aTreatment optimisation in drug development _b: study : Panel for the Future of Science and Technology _c/ EPRS - European Parliamentary Research Service |
| 260 |
_aBrussels : _bEuropean Union, _cMarch 2020 |
||
| 300 |
_aV, 70 p. _c; 1 documento PDF |
||
| 336 |
_2isbdcontent _atexto |
||
| 337 |
_2isbdcontent _aelectrónico |
||
| 338 |
_2rdacarrier _arecurso en línea |
||
| 504 | _aBibliografía: p. 66-70 | ||
| 520 | _aThe development of novel health technologies is a complex and costly process that follows an extensive set of regulatory guidelines and legal provisions intended to ensure that the treatments reach the patients that need them in a highly controlled and standardised manner | ||
| 540 | _aReproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy. | ||
| 650 | 7 |
_aSanidad digital _2 _92065 |
|
| 653 | _atreatment optimisation | ||
| 653 | _aclinical drug | ||
| 653 | _atreatment | ||
| 653 | _apatient | ||
| 653 | _apublic health | ||
| 653 | _aindustry | ||
| 710 |
_aParlamento Europeo. _bDirección General de Servicios de Estudios Parlamentarios _93675 |
||
| 856 | 4 | 2 |
_uhttps://www.europarl.europa.eu/RegData/etudes/STUD/2020/641511/EPRS_STU(2020)641511_EN.pdf _x0 _yAcceso al documento _qpdf |
| 942 |
_2z _cINF |
||